These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38644793)

  • 41. DLQI scores in vitiligo: reliability and validity of the Persian version.
    Aghaei S; Sodaifi M; Jafari P; Mazharinia N; Finlay AY
    BMC Dermatol; 2004 Aug; 4():8. PubMed ID: 15294022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients.
    Handa S; Pandhi R; Kaur I
    J Dermatol; 2001 Sep; 28(9):461-6. PubMed ID: 11603385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success.
    Batchelor JM; Tan W; Tour S; Yong A; Montgomery AA; Thomas KS
    Br J Dermatol; 2016 Feb; 174(2):386-94. PubMed ID: 26409256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of long-wavelength ultraviolet A1 (UVA1) in acral vitiligo.
    El-Zawahry BM; Elmasry MF; Ragab A
    J Cosmet Dermatol; 2019 Aug; 18(4):1155-1160. PubMed ID: 30375144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness of therapeutic interventions on quality of life for vitiligo patients: a systematic review.
    Chan MF; Chua TL
    Int J Nurs Pract; 2012 Aug; 18(4):396-405. PubMed ID: 22845640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo.
    Bilgiç O; Bilgiç A; Akiş HK; Eskioğlu F; Kiliç EZ
    Clin Exp Dermatol; 2011 Jun; 36(4):360-5. PubMed ID: 21198786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo.
    Bonotis K; Pantelis K; Karaoulanis S; Katsimaglis C; Papaliaga M; Zafiriou E; Tsogas P
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):45-9. PubMed ID: 26713637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.
    Eleftheriadou V; Thomas KS; Whitton ME; Batchelor JM; Ravenscroft JC
    Br J Dermatol; 2012 Oct; 167(4):804-14. PubMed ID: 22591025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Family vitiligo impact scale: A scale to measure the quality-of-life of family members of patients with vitiligo.
    Agrawal S; Satapathy S; Gupta V; Sreenivas V; Khaitan BK; Ramam M
    Indian J Dermatol Venereol Leprol; 2021; 88(1):32-39. PubMed ID: 34379960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation study of the Vitiligo Extent Score-plus.
    van Geel N; Wolkerstorfer A; Lommerts JE; Ezzedine K; Eleftheriadou V; Hamzavi I; Harris J; Picardo M; Taieb A; Prinsen CAC; Bekkenk M; Speeckaert R
    J Am Acad Dermatol; 2018 May; 78(5):1013-1015. PubMed ID: 29180094
    [No Abstract]   [Full Text] [Related]  

  • 51. Guideline for the diagnosis and management of vitiligo.
    Gawkrodger DJ; Ormerod AD; Shaw L; Mauri-Sole I; Whitton ME; Watts MJ; Anstey AV; Ingham J; Young K; ; ; ;
    Br J Dermatol; 2008 Nov; 159(5):1051-76. PubMed ID: 19036036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of the quality of life of pediatric patients with the major chronic childhood skin diseases.
    Manzoni AP; Pereira RL; Townsend RZ; Weber MB; Nagatomi AR; Cestari TF
    An Bras Dermatol; 2012; 87(3):361-8. PubMed ID: 22714749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significant immediate and long-term improvement in quality of life and disease coping in patients with vitiligo after group climatotherapy at the Dead Sea.
    Krüger C; Smythe JW; Spencer JD; Hasse S; Panske A; Chiuchiarelli G; Schallreuter KU
    Acta Derm Venereol; 2011 Mar; 91(2):152-9. PubMed ID: 21240455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Camouflage for patients with vitiligo vulgaris improved their quality of life.
    Tanioka M; Yamamoto Y; Kato M; Miyachi Y
    J Cosmet Dermatol; 2010 Mar; 9(1):72-5. PubMed ID: 20367677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index.
    Coias J; Hynan LS; Pandya AG
    J Am Acad Dermatol; 2018 May; 78(5):1015-1016. PubMed ID: 29180097
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparative Evaluation of Efficacy and Safety of Tacrolimus and Dinoprostone Following Dermabrasion in Stable Vitiligo.
    Kaur J; Kumar S; Brar BK; Boparai AS
    J Drugs Dermatol; 2021 May; 20(5):519-522. PubMed ID: 33938708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cessation of spread as a treatment objective in vitiligo: perception from the patients' point of view.
    van Geel N; Desmedt V; De Schepper S; Boone B; Lapeere H; Speeckaert R
    Br J Dermatol; 2016 Apr; 174(4):922-4. PubMed ID: 26556484
    [No Abstract]   [Full Text] [Related]  

  • 58. Assessment of vitiligo severity: patient-reported estimates are not accurate.
    Ukoha UT; Sosa JJ; Hynan LS; Pandya AG
    Br J Dermatol; 2015 Nov; 173(5):1325-6. PubMed ID: 25833124
    [No Abstract]   [Full Text] [Related]  

  • 59. Assessment scale used in vitiligo.
    Hossain D
    J Am Acad Dermatol; 2005 Jun; 52(6):1110-1. PubMed ID: 15928648
    [No Abstract]   [Full Text] [Related]  

  • 60. Identification of categories at risk for high quality of life impairment in patients with vitiligo.
    Sampogna F; Raskovic D; Guerra L; Pedicelli C; Tabolli S; Leoni L; Alessandroni L; Abeni D
    Br J Dermatol; 2008 Aug; 159(2):351-9. PubMed ID: 18565189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.